NZ589844A - Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors - Google Patents

Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors

Info

Publication number
NZ589844A
NZ589844A NZ589844A NZ58984409A NZ589844A NZ 589844 A NZ589844 A NZ 589844A NZ 589844 A NZ589844 A NZ 589844A NZ 58984409 A NZ58984409 A NZ 58984409A NZ 589844 A NZ589844 A NZ 589844A
Authority
NZ
New Zealand
Prior art keywords
pi3k
phosphatidylinositol
thiophene
kinase
inhibitors
Prior art date
Application number
NZ589844A
Other languages
English (en)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ589844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ589844A publication Critical patent/NZ589844A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ589844A 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors NZ589844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
NZ589844A true NZ589844A (en) 2012-11-30

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589844A NZ589844A (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors

Country Status (21)

Country Link
US (3) US8183240B2 (enExample)
EP (1) EP2313399B1 (enExample)
JP (1) JP5596026B2 (enExample)
KR (1) KR20110018451A (enExample)
CN (1) CN102066365A (enExample)
AU (1) AU2009260782B2 (enExample)
BR (1) BRPI0914223A2 (enExample)
CA (1) CA2727069A1 (enExample)
CL (1) CL2010001474A1 (enExample)
CO (1) CO6331431A2 (enExample)
CR (1) CR20110032A (enExample)
EA (1) EA201170052A1 (enExample)
ES (1) ES2491522T3 (enExample)
GE (1) GEP20125650B (enExample)
IL (1) IL210055A0 (enExample)
MA (1) MA32468B1 (enExample)
MX (1) MX2010014125A (enExample)
NZ (1) NZ589844A (enExample)
UA (1) UA106206C2 (enExample)
WO (1) WO2009154741A1 (enExample)
ZA (1) ZA201008875B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN102066365A (zh) * 2008-06-19 2011-05-18 米伦纽姆医药公司 噻吩或噻唑衍生物和其作为pi3k抑制剂的用途
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603214A4 (en) * 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
TW201331194A (zh) * 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
CA2865642C (en) * 2012-03-14 2021-10-26 Salk Institute For Biological Studies Adenoviral tumor diagnostics
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
KR20160115999A (ko) * 2014-02-14 2016-10-06 더 유니버시티 오브 브리티쉬 콜롬비아 치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
JP7498199B2 (ja) * 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
CN115103840B (zh) 2019-12-20 2025-07-22 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101932587A (zh) * 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
WO2009094224A1 (en) * 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN102066365A (zh) * 2008-06-19 2011-05-18 米伦纽姆医药公司 噻吩或噻唑衍生物和其作为pi3k抑制剂的用途

Also Published As

Publication number Publication date
US20100075951A1 (en) 2010-03-25
US20120202812A1 (en) 2012-08-09
ES2491522T3 (es) 2014-09-08
US20130217689A1 (en) 2013-08-22
JP5596026B2 (ja) 2014-09-24
CR20110032A (es) 2011-03-14
CL2010001474A1 (es) 2011-04-29
AU2009260782A1 (en) 2009-12-23
CA2727069A1 (en) 2009-12-23
CO6331431A2 (es) 2011-10-20
GEP20125650B (en) 2012-09-25
US8440664B2 (en) 2013-05-14
MX2010014125A (es) 2011-02-24
AU2009260782B2 (en) 2014-12-11
IL210055A0 (en) 2011-02-28
BRPI0914223A2 (pt) 2019-09-24
US8183240B2 (en) 2012-05-22
EA201170052A1 (ru) 2011-06-30
UA106206C2 (ru) 2014-08-11
CN102066365A (zh) 2011-05-18
MA32468B1 (fr) 2011-07-03
WO2009154741A8 (en) 2010-03-25
ZA201008875B (en) 2012-02-29
WO2009154741A1 (en) 2009-12-23
KR20110018451A (ko) 2011-02-23
JP2011524904A (ja) 2011-09-08
EP2313399A1 (en) 2011-04-27
EP2313399B1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
UA106206C2 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
MX340714B (es) Inhibidores de hsp90.
PH12013500274A1 (en) Heteroaryls and uses thereof
WO2010003475A3 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
HRP20180662T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
GEP20125652B (en) cMET INHIBITORS
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
UA107784C2 (en) Inhibitor of melanin production
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
IL208233A0 (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
MX2012000178A (es) 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX342960B (es) Derivados de cromeno.
MX2011007232A (es) Derivados de benzotiazolona.
UA106628C2 (uk) Метилпіролопіримідинкарбоксаміди
MX2011007641A (es) Nuevos compuestos heterociclicos como inhibidores de metap-2.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUN 2016 BY HENRY HUGHES

Effective date: 20130604

LAPS Patent lapsed